- Home
- TSVT
TSVT
2seventy bio Inc.
as 03-25-2025 2:34pm EST
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 258.9M | IPO Year: | N/A |
| Target Price: | $7.60 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.29 - $5.99 | Next Earning Date: | 05-07-2025 |
| Revenue: | $45,620,000 | Revenue Growth: | -68.73% |
| Revenue Growth (this year): | -51.78% | Revenue Growth (next year): | 35.12% |
Stock Insider Trading Activity of 2seventy bio Inc. (TSVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Snow Jessica | TSVT | Chief Operating Officer | Mar 17 '25 | Sell | $4.95 | 2,298 | $11,363.61 | 254,193 | |
| Eatwell Victoria | TSVT | Chief Financial Officer | Mar 17 '25 | Sell | $4.95 | 2,592 | $12,817.44 | 444,387 | |
| Kynam Global Healthcare Master Fund, LP | TSVT | 10% Owner | Mar 11 '25 | Sell | $4.93 | 16,238,047 | $80,053,571.71 | 0 | |
| Snow Jessica | TSVT | See Remarks | Jan 3 '25 | Sell | $2.79 | 8,138 | $22,851.80 | 254,193 | |
| Baird William D III | TSVT | President and CEO | Jan 3 '25 | Sell | $2.86 | 32,481 | $95,240.87 | 862,126 | |
| Leschly Nick | TSVT | Director | Jan 3 '25 | Sell | $2.86 | 86,870 | $254,901.23 | 1,234,498 | |
| Eatwell Victoria | TSVT | Chief Financial Officer | Jan 3 '25 | Sell | $2.86 | 1,110 | $3,243.58 | 444,387 |
Latest 2seventy bio Inc. News
TSVT Breaking Stock News: Dive into TSVT Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
Exploring High Growth Tech Stocks In The US March 2025
Business Wire
15 days ago
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
Business Wire
a month ago
2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference
Simply Wall St.
a month ago
3 US Penny Stocks With Market Caps Under $200M
Business Wire
2 months ago
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
Simply Wall St.
2 months ago
US Penny Stocks Spotlight: uCloudlink Group Among 3 Noteworthy Picks
Simply Wall St.
3 months ago
US Penny Stocks To Watch In December 2024
Simply Wall St.
4 months ago
US$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results
Compare TSVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TSVT 2seventy bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.